Molecular classification of breast cancer

We performed an exploratory analysis of the transcriptional, immunobiological and prognostic associations of TP53 mutations within the gene expression-based consensus

The seven molecular classes from TCGA are defined by either overexpression or fusion of one of four ETS transcription factors (ERG, ETV1, ETV4, or FLI1) or by somatic point

The inclusion criteria of this literature review were based on the PICOS-framework: (i) population: Human breast cancer patients; (ii) intervention: either of the molecular genetic

Since our model of EGF-stimulated mammary epithelial cells mirrors gene expression patterns in breast cancer patients, it has been employed herein with the aim of uncovering

Two established xenograft models representing basal-like and luminal-like breast cancer were used to study bevacizumab treatment response on the metabolic and gene expression

van’t Veer et al., “Validation and clinical utility of a 70-gene prognostic signature for women with node- negative breast cancer,” Journal of the National Cancer Institute, vol.

We analyzed the existence and expression of the ∆p53 iso- form in breast tumors from patients with advanced dis- ease at the mRNA level and asked whether mutations present in

Conclusions: FGD5 is a new prognostic marker in breast cancer, and increased copy number is associated with higher tumour proliferation and poorer long-term prognosis.. Key